Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
New data shows the combination of Akero’s efruxifermin and Ozempic can reduce liver fat, boosting both drugs’ prospects in NASH.
News
Janssen present positive follow-up data for first in line therapy for lung cancer
Janssen reports positive results for Talquetamab in Multiple myeloma
ASCO 2023: Research backs chemo-only approach for some rectal cancer patients
Servier’s Phase III INDIGO trial of vorasidenib meets endpoints
AstraZeneca reports positive results from ADAURA Phase III trial
Vivavision’s Phase IIa study of ophthalmic solution meets primary endpoints
Chimeric launches Phase IB trial of glioblastoma multiforme therapy
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
